The FDA has issued a warning letter, dated September 18, 2026 and made public in late September, to Empower Clinic Services (doing business as Empower Pharmacy), one of the largest compounding pharmacies supplying telehealth and clinic customers nationwide. The letter followed an FDA inspection of the company's Houston, Texas facility conducted from November 3 to 14, 2025.
What the FDA Found
The letter centers on compounded combination products, including tirzepatide paired with niacinamide and semaglutide paired with cyanocobalamin (vitamin B12). FDA said these products appeared to be essentially copies of already FDA-approved semaglutide and tirzepatide drugs, which would disqualify them from the limited exemptions that normally let compounding pharmacies operate outside full FDA drug-approval requirements.
A central piece of that exemption, known as Section 503A, requires that a compounded drug not be "essentially a copy" of an approved drug unless a prescriber has documented a specific clinical reason the patient needs a different version. FDA investigators reported finding prescriptions that lacked this documented determination, or that repeated identical boilerplate justifications across a large number of patient records — a pattern regulators have flagged in other compounding enforcement actions this year as well.
The letter separately cited sterility and current good manufacturing practice (CGMP) problems for products meant to be sterile, including what FDA described as insanitary conditions, inadequate dynamic smoke studies used to verify clean-air workflow, and gaps in how media-fill tests — a standard way of validating sterile production — were documented. FDA also cited broader issues with facility maintenance, process validation, environmental monitoring, and quality-unit oversight.
Why "Essentially a Copy" Matters
Compounding pharmacies exist to prepare individualized medications, such as a drug in a different strength or without an allergen, for patients whose medical needs aren't met by a commercially available product. They are not meant to mass-produce near-identical versions of an already-approved drug just because the compounded version may be cheaper or combined with an additive like a vitamin. When FDA determines a product is "essentially a copy," the compounder loses its exemption from the full drug-approval requirements, labeling rules, and CGMP standards that apply to companies like Novo Nordisk and Eli Lilly. This letter is one of several the agency has issued this year applying that theory specifically to compounded tirzepatide and semaglutide products.
The Broader Compounding Context
Compounded versions of tirzepatide and semaglutide were produced legally in large volume during the years both drugs appeared on the FDA's official drug shortage list, which allowed broader compounding under separate shortage-related exemptions. FDA ended that enforcement discretion for compounded tirzepatide in March 2025 and for compounded semaglutide in April 2025, after determining the shortages had resolved. Compounding of these drugs hasn't stopped since then, but it is now subject to the stricter, patient-specific standards under Section 503A rather than the shortage exemption, and this letter is an example of FDA applying that stricter standard.
What Happens Next
Empower has 15 working days from the date of the letter to respond in writing with corrective actions. FDA noted it could not fully evaluate some of the corrective steps the company had already proposed because supporting documentation was incomplete. The letter itself did not announce a recall or an order to stop sales; warning letters are a notice of violations and a request for correction, not an immediate market withdrawal, though FDA can escalate to further enforcement if a company doesn't adequately respond.
What It Means If You Use a Compounded GLP-1
Compounded semaglutide and tirzepatide products, regardless of pharmacy, are not FDA-approved drugs: the agency does not review them for safety, effectiveness, or manufacturing quality the way it reviews Ozempic, Wegovy, Mounjaro, or Zepbound. If you're using a compounded GLP-1 product, this is a reasonable moment to ask your prescriber or pharmacy directly how they document medical necessity for any added ingredients, and whether the pharmacy has had recent FDA inspection findings. As always, any change in a GLP-1 treatment plan should go through a licensed clinician rather than being decided unilaterally based on a news report.